Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Enliven Therapeutics, Inc.ELVN · Entity 4024 | Director | February 06, 2025 | February 10, 2025 |
| MoonLake ImmunotherapeuticsMLTX · Entity 4785 | Director | June 17, 2026 | June 18, 2026 |
| OnKure Therapeutics, Inc.OKUR · Entity 6550 | Director | August 07, 2026 | August 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Enliven Therapeutics, Inc.
Report date February 06, 2025 · Filed February 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.47 · Expires 2035-02-06 | Direct | 20,491 |
Reported balance
After 2025-02-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-02-06 · Grant · Acquired 20,491 · Balance 20,491 F1: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2025 annual meeting of the Issuer's stockholders or (ii) the date of the 2026 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2025 annual meeting of the Issuer's stockholders or (ii) the date of the 2026 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date.
MoonLake Immunotherapeutics
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to BuySEC Table II · derivative / convertible security · Conversion / exercise price $19.19 · Expires 2036-06-17 | Direct | 22,195 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 22,195 · Balance 22,195 F1: This option represents a right to purchase a total of 22,195 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to the Reporting Person's continued service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase a total of 22,195 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to the Reporting Person's continued service to the Issuer.
OnKure Therapeutics, Inc.
Report date August 07, 2026 · Filed August 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14 · Expires 2036-08-06 | Direct | 22,350 |
Reported balance
After 2026-08-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-07 · Grant · Acquired 22,350 · Balance 22,350 F1: 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 07, 2026 Filed Aug 11, 2026 20:39 UTC | OnKure Therapeutics, Inc. OKUR · Entity 6550 | GrantStock Option (right to buy) · Derivative | 22,350 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0001921956-26-000003 · form4-08112026_080848.xml · derivative · entry 1 Phillips Andrew John · CIK 0001921956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,350 Underlying: Class A Common Stock · 22,350 shares Expires 2036-08-06 F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 22:45 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | GrantOption to Buy · Derivative | 22,195 | $0.00 Strike: $19.19 | $0.00 |
DisclosureSEC source: 0001213900-26-070258 · ownership.xml · derivative · entry 1 Phillips Andrew John · CIK 0001921956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,195 Underlying: Class A ordinary shares, par value $0.0001 per share · 22,195 shares Expires 2036-06-17 F1 · derivative.exercise_date: This option represents a right to purchase a total of 22,195 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 22:26 UTC | OnKure Therapeutics, Inc. OKUR · Entity 6550 | GrantStock Option (right to buy) · Derivative | 7,650 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0001921956-26-000002 · form4-06082026_100605.xml · derivative · entry 1 Phillips Andrew John · CIK 0001921956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,650 Underlying: Class A Common Stock · 7,650 shares Expires 2036-06-03 F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 13:05 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | GrantOption to Buy · Derivative | 6,682 | $0.00 Strike: $48.83 | $0.00 |
DisclosureSEC source: 0001213900-25-052365 · ownership.xml · derivative · entry 1 Phillips Andrew John · CIK 0001921956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,682 Underlying: Class A ordinary shares, par value $0.0001 per share · 6,682 shares Expires 2035-06-05 F1 · derivative.exercise_date: This option represents a right to purchase a total of 6,682 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 5, 2026 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 28, 2025 Filed May 30, 2025 20:54 UTC | OnKure Therapeutics, Inc. OKUR · Entity 6550 | GrantStock Option (right to buy) · Derivative | 7,650 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001415889-25-015019 · form4-05302025_080528.xml · derivative · entry 1 Phillips Andrew John · CIK 0001921956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,650 Underlying: Class A Common Stock · 7,650 shares Expires 2035-05-27 F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of May 28, 2026 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 22:40 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantStock Option (right to buy) · Derivative | 20,491 | $0.00 Strike: $22.47 | $0.00 |
DisclosureSEC source: 0001415889-25-003524 · form4-02102025_100239.xml · derivative · entry 1 Phillips Andrew John · CIK 0001921956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,491 Underlying: Common Stock · 20,491 shares Expires 2035-02-06 F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2025 annual meeting of the Issuer's stockholders or (ii) the date of the 2026 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date. Read SEC document |
| October 04, 2024 Filed Oct 8, 2024 23:28 UTC | OnKure Therapeutics, Inc. OKUR · Entity 6550 | GrantStock Option (right to buy) · Derivative | 15,300 | $0.00 Strike: $18.20 | $0.00 |
DisclosureSEC source: 0001415889-24-024920 · form4-10082024_111029.xml · derivative · entry 1 Phillips Andrew John · CIK 0001921956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,300 Underlying: Class A Common Stock · 15,300 shares Expires 2034-10-03 F1 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest on November 4, 2024 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 21:00 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | GrantOption to Buy · Derivative | 7,688 | $0.00 Strike: $42.44 | $0.00 |
DisclosureSEC source: 0001213900-24-050833 · ownership.xml · derivative · entry 1 Phillips Andrew John · CIK 0001921956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,688 Underlying: Class A ordinary shares, par value $0.0001 per share · 7,688 shares Expires 2034-06-06 F1 · derivative.exercise_date: This option represents a right to purchase a total of 7,688 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 6, 2025, (ii) the date of the Issuer's next annual general meeting of shareholders and (iii) the date of a Change in Control (as defined in the MoonLake Immunotherapeutics 2022 Equity Incentive Plan) of the Issuer, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 02:04 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantStock Option (right to buy) · Derivative | 16,835 | $0.00 Strike: $14.85 | $0.00 |
DisclosureSEC source: 0001415889-24-004028 · form4-02162024_020201.xml · derivative · entry 1 Phillips Andrew John · CIK 0001921956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,835 Underlying: Common Stock · 16,835 shares Expires 2034-02-12 F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2024 annual meeting of the Issuer's stockholders or (ii) the date of the 2025 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date. Read SEC document |
| February 13, 2024 Filed Feb 21, 2024 00:35 UTC Amendment | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantStock Option (right to buy) · Derivative | 23,364 | $0.00 Strike: $14.85 | $0.00 |
DisclosureSEC source: 0001415889-24-004493 · form4a-02212024_120239.xml · derivative · entry 1 Phillips Andrew John · CIK 0001921956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,364 Underlying: Common Stock · 23,364 shares Expires 2034-02-13 F1 · shares: The original Form 4 filed February 15, 2024 incorrectly reported the number of shares subject to the option grant. F2 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2024 annual meeting of the Issuer's stockholders or (ii) the date of the 2025 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date. F1 · derivative.underlying_shares: The original Form 4 filed February 15, 2024 incorrectly reported the number of shares subject to the option grant. F1 · balance_after: The original Form 4 filed February 15, 2024 incorrectly reported the number of shares subject to the option grant. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:47 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | GrantOption to Buy · Derivative | 11,297 | $0.00 Strike: $29.18 | $0.00 |
DisclosureSEC source: 0001213900-23-048193 · ownership.xml · derivative · entry 1 Phillips Andrew John · CIK 0001921956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,297 Underlying: Class A ordinary shares, par value $0.0001 per share · 11,297 shares Expires 2033-06-08 F1 · derivative.exercise_date: This option represents a right to purchase a total of 11,297 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 8, 2024 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 23, 2023 Filed Apr 7, 2023 00:20 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantStock Option (right to buy) · Derivative | 27,567 | $0.00 Strike: $25.28 | $0.00 |
DisclosureSEC source: 0001209191-23-023668 · doc4.xml · derivative · entry 1 Phillips Andrew John · CIK 0001921956 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,567 Underlying: Common Stock · 27,567 shares Expires 2033-02-23 F1 · derivative.exercise_date: 1/36th of the shares subject to the option will vest on March 23, 2023 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| April 06, 2022 Filed May 5, 2022 21:45 UTC | MoonLake Immunotherapeutics MLTX · Entity 4785 | GrantOption to Buy · Derivative | 45,000 | $0.00 Strike: $12.25 | $0.00 |
DisclosureSEC source: 0001213900-22-024301 · ownership.xml · derivative · entry 1 Phillips Andrew John · CIK 0001921956 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Class A ordinary shares, par value $0.0001 per share · 45,000 shares Expires 2032-04-06 F1 · derivative.exercise_date: Dr. Phillips was granted 45,000 options on April 6, 2022 pursuant to the MoonLake Immunotherapeutics 2022 Equity Incentive Plan (the "Plan"), vesting one-third on each of April 6, 2023, April 6, 2024 and April 6, 2025, in each case, subject to the terms of the Plan. Each option represents the right to acquire one Class A ordinary share, par value $0.0001 per share, of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.